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The incidence of end-stage renal disease (ESRD) is increasing
worldwide. When compared to dialysis, renal transplantation
(RT) leads to a  survival advantage and to an  improvement
in quality of life in most ESRD patients.1 Additionally, from
a societal perspective, RT is the most cost-effective modal-
ity of renal replacement therapy (RRT)2,3 for eligible patients.
In the last decades, RT has prolonged and improved the  lives
of hundreds of thousands of patients worldwide. Neverthe-
less, although the prevalence of ESRD is increasing in  most
countries, transplantation rates have not kept pace. In 2016,
there were nearly 2000 patients waiting for RT in  Portugal
and only 500 kidney transplants were performed, illustrating
the clear discrepancy between the number of transplants and
the number of patients awaiting for transplantation. Thus,
the widening gap between the number of deceased donors
and the need for RT  has driven interest in incentivizing living
kidney donation (LKD). Besides alleviating the gap between
the supply and the demand of kidneys, living donor trans-
plants are associated with improved outcomes4,5 allowing for
preemptive transplantation (i.e. transplantation before ini-
tiating dialysis), which is  associated with a  better survival
rate.6,7 Considering the growing public awareness of the organ
shortage crisis and the known advantages of LKD, there has
been an increase in LKD over the last decade.8 Currently, in
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our country, LKD relies on donor’s altruistic initiative, with
no possibility of compensation or incentive other than reim-
bursement for  expenses related to the donation. Considering
the benefits of LKD, multiple strategies to  increase living
donation have been proposed, including the promotion of
financial incentives for living donors.9–12 In the last  years,
surveys have been performed worldwide in  order to access
the public opinion13,14 and the Nephrologist’s perceptions
and attitudes about rewards and compensations for kidney
donation.15,16 A  general consensus has not been reached,
considering that public and professional opinions are influ-
enced by social, demographic, ethnic, sociological and cultural
bias.
Donor  selection  and  ethical  problems  regarding
financial  incentives  for  living  kidney  donation
Donor selection criteria are well defined by the World Health
Organization (WHO): ‘Live donations are acceptable when the
donor’s informed and voluntary consent is obtained, when
professional care of donors is  ensured and follow-up is  well
organized, and when selection criteria for donors are scrupu-
lously applied and monitored’.17
Conversely, financial incentives for LKD are prohibited by
the Declaration of Istanbul and by law in most countries18
despite the fact that the subject of payment has been exten-
sively debated. Some authorities believe that any payment
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could lead to commercialization and would undermine trans-
plant efforts, while others inferred that providing incentives
will lead to  an increase in  organ donation. So, the potential
use of financial compensation to increase LKD rates remains
controversial. Those who favor payment believe that paid LKD
would decrease waitlist deaths ant that remuneration could be
ethical with respect to the donor19,20;  those who are against
payment defend that potential donor would be  subject of
coercion, undue influence and body commodification.21 A  key
question is whether organs donors think motivations to act
altruistically will be  jeopardized if financial rewards or pay-
ments will be  offered as incentives to donate organs, and
whether they have an  economic right to be compensated for
cost incurred by donation.
From the ethical point of view, four categories of ethi-
cal concern relating to financial rewards  and compensation
for organ donation are unveiled22,23: undue inducement,
unjust inducement, crowding out of intrinsic motivation
to donate and commodification of the body. The ethical
basis of living donation is nonmaleficience to the  donor and
respect for donor autonomy. Nonmaleficience entails that
the donor should be in excellent health; respect for auton-
omy requires an informed consent from the  donors. The
major concern related to “undue inducement” is that pay-
ment for living kidney donation will undermine informed
consent by coercing individuals into accepting risks that they
would otherwise not accept, compelling people to  donate
and undermining autonomy. Inducements are not inher-
ently unethical but become so when their magnitude is  so
irresistible that they distort peoples’ judgment, encouraging
potential donors to engage in  activities that contravene their
interest.
The concern for “unjust inducement” refers to coercing
poor and/or vulnerable to donate, fearing that financial com-
pensation for donation would take advantage of impoverished
individuals who  are presumed to be more  vulnerable to donate
for compensation.“Crowding out” critique relates to the fact
that compensation might reduce organ donation, discourag-
ing altruistic donors, who would become disinclined to  donate
when a financial compensation exists.24–26
Finally, the “commodification of the  body” critique claims
the degradation of personal dignity, considering that the
human body has inestimable intrinsic value and allowing
someone to sell a  part of the body degrades that person’s
dignity.
Types  of  rewarded  compensations  for  LKD
Rewarded compensation for LKD is often not well defined
in literature. Terms like “rewarded gifting”, “rewarded
compensation”, “merited recompense”, “gratitudinal gifts”
or “outright payment for kidneys” are obscure. Typically,
rewarded compensation refers to financial inducements to
donate, entailing profit of some kind.
One type of donor compensation is  reimbursement of
all expenses, such as  travel expenses and follow-up care
and/or lost wages.  The WHO  guiding principles permits reim-
bursement for ‘reasonable and verifiable expenses incurred
by the donor, including loss of income’.17 The European
Convention on Human Rights and Biomedicine also states
that the  prohibition of financial gain ‘shall not prevent pay-
ments which do not constitute a financial gain or a comparable
advantage’.27 Despite the fact that such payments are legal,
many  donors are unaware of their benefits and do not require
them.
Another type of compensation, which is  controversial, is
the provision of direct or indirect financial incentives beyond
expenses. Indirect incentives may  take the form of “in-kind
rewards”, such as  health or life insurance, contribution to
the donor retirement fund or income tax credit, so people
who are desperate for cash would not be tempted to sell a
kidney.
Incentives could also apply to  all living donors or only
a subset, such as donors who donate to a global waiting
list program. Either hybrid systems, incorporating altruistic
donation alongside a  regulated reward compensation system,
either direct payments to all living donors, could potenti-
ate “crowding out” and dissuade genuine altruists. Despite
these concerns, the World Medical Association and Coun-
cil  of Europe28 distinguish between the commercialization
of human tissue and organs and compensation for living
donation. Additionally, the Nuffield Council on Bioethics29
defines non-altruistically focused financial incentives to
reward living donor and their families from altruisti-
cally focused recompense, which includes compensation
for inconvenience, discomfort and time and reimbursement
of direct expenses, such as  medical expenses and lost
earnings.
Does  financial  compensation  for  living  kidney
donation  change  willingness  to  donate?
Concerns that compensation for LKD would lead to undue
inducement and other ethical dilemmas are plausible, never-
theless no evidence-based data from clinical trials of donor
payment are available because such trials are not ethically
acceptable. The majority of peer-review reports concerning
this issue are based on opinion and direct interview to  com-
munity members. Venkataramani et  al.30 studied the impact
of tax deductions for donor-related expenses in certain USA
sates and found no evidence that tax incentives dispropor-
tionately affected the  willingness of lower-income groups to
donate. Also, tax deductions, also failed in increasing LKD
rates. Gordon et al.31 studied the amount of financial com-
pensation which would generate motivation to donate to
family/friend or strangers. They conclude that respondents’
willingness to donate would not change in 70%  of participants
and observed a little practical impact of financial compensa-
tion in LKD. The majority of the public surveyed perceived
that financial compensation for living donors is acceptable,
but fewer respondents considered financial compensation to
themselves to donate acceptable. In other words, these results
suggest that financial rewards would make a  little difference
in individuals’ decision to donate and policies in support of
financial compensation would have relatively little traction in
increasing living donation rates. Nevertheless, is important to
consider that responses to survey scenarios may  not reflect
how people would actually behave if faced with the possibility
to be paid for LKD.
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Strategies  to increase  kidney  donation
Expense reimbursement is ethically acceptable and performed
in some countries as it is not considered a financial benefit.
However it does not seem to  lead to a  meaningful increase
in kidney donation. Therefore, other potential strategies that
may increase KT need to be examined, despite some possible
incremental costs.
Numerous approaches could potentially lead to an increase
in the pool of donors: the introduction of deceased donors’ reg-
istries, national and local awareness campaigns educational
efforts and paired exchange programs, among others. Further-
more, removal of restrictions regarding anonymous donation,
could be a way to make alternative living donation programs
possible. Such programs should be implemented in the frame
of international standards to ensure quality and safety of
donors and recipients.
Conclusion
Transplantation rates have not increased over the last  decade
and the deceased donor waiting list continues to grow. Cur-
rently, in Portugal, there are no incentives for living donors,
although reimbursement of expenses incurred by donor is per-
mitted. Apart from altruistic motives of family or close friends,
it  is important to think about the ethical contours of the  social
world in which organ transplants take place and all efforts
should be done to assure the ethical basic principles of LKD.
There is currently little evidence to support arguments that
financial compensation for LKD will change willingness to
donate, so the above mentioned strategies to  increase kidney
donation should be considered.
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